Acute Lymphoblastic Leukemia Presenting With Initial Hyperbilirubinemia and Significantly Elevated Liver Transaminases: A Rare Pediatric Case With Unadjusted Chemotherapy

Abstract

Acute lymphoblastic leukemia (ALL) rarely presents with initial liver failure. We describe a 9-year-old boy with no past medical history who presented with jaundice, hyperbilirubinemia (total bilirubin 13.1 mg/dL), and significantly elevated transaminases (ALT 1283 U/L, AST 1325 U/L). Bone marrow aspiration confirmed precursor B-cell ALL. Despite severe hepatic dysfunction, full-dose induction chemotherapy was administered following corticosteroid therapy, leading to rapid improvement in liver function and normalization by day 29. No complications were observed, and at the end of induction, minimal residual disease was 0.001%. This case of successful unadjusted chemotherapy, with leukemic infiltration identified as the etiology of hepatitis, underscores the importance of early diagnosis, multidisciplinary management, close monitoring, and highlights the need for further investigation into safe treatment protocols in such cases.

Keywords

ALL jaundice hyperbilirubinemia pediatric oncology chemotherapy hepatitis case report liver failure

Introduction

Acute Lymphoblastic Leukemia (ALL) is the most prevalent type of cancer in children.¹ Over 80% of ALL cases represent B-cell Acute Lymphoblastic Leukemia (B-ALL), where genetic mutations disrupt differentiation at the precursor B-cell stage, sustaining survival and proliferation of malignant cells.² The infiltration and proliferation of malignant lymphoid cells may extend beyond the bone marrow (BM) to affect extramedullary organs, like the central nervous system, spleen, lymph nodes, kidneys, testes, and liver, showing the systemic nature of ALL.^2-4

Liver involvement is a common manifestation in ALL patients, with presentations ranging from asymptomatic hepatosplenomegaly in about 68% of cases to severe fulminant hepatitis.^4-6 However, Acute Liver Failure (ALF) as initial ALL presentation is rarely reported.³ While drug-induced hepatotoxicity is a known complication of chemotherapy in ALL patients, initial liver failure can complicate treatment and may require dose modification to mitigate toxicity.^3,7

In this case report, we describe a rare presentation of B-ALL manifesting as ALF with jaundice and significantly elevated transaminases, underscoring the therapeutic challenges in managing ALL with concurrent hepatic impairment.

Case Presentation

A 9-year-old Caucasian boy presented to the pediatric clinic with a 3-day history of anorexia, nausea, non-bilious and non-bloody vomiting, jaundice with scleral and skin icterus, and 2 months of fatigue. He reported no abdominal pain, fever, diarrhea, recent bleeding, bruising, travel, or trauma. The patient, an only child born from a normal pregnancy, had a BMI of 15.9 (44th percentile), normal developmental milestones, no nutritional or vitamin deficiency, and was fully vaccinated, including against tuberculosis and hepatitis B. He had no history of chronic diseases such as chronic liver failure, hospitalization, tuberculosis exposure, or use of potentially hepatotoxic agents in the last month. There was no family history of liver disease, hereditary disorders, or malignancies.

On examination, the abdomen was soft and non-tender, with a liver span of approximately 7 cm, measured by percussion. The spleen was not palpable, and no masses, ascites, or signs of peritonitis were noted. There was no lymphadenopathy, spider angiomas, palmar erythema, or pedal edema. Testicular and neurological exams were normal, and vital signs were age-appropriate.

The patient was hospitalized for further evaluation. Initial differential diagnoses included viral hepatitis, obstructive biliary diseases, hemophagocytic lymphohistiocytosis (HLH), autoimmune hepatitis, hemolytic anemia, and malignancies.

Abdominal ultrasound revealed a normal common bile duct, no organomegaly of the liver or spleen, no focal hepatic lesions, and para-aortic lymph nodes measuring up to 15 mm in diameter. Initial laboratory tests revealed significant liver dysfunction with: total bilirubin 13.1 mg/dL, direct bilirubin 6.43 mg/dL, alanine aminotransferase (ALT) 1283 U/L, aspartate aminotransferase (AST) 1325 U/L, alkaline phosphatase (ALP) 1150 U/L, and γ-glutamyl transferase 44 U/L. Coagulation results were also prothrombin time at 14.5 seconds (normal: 11-13.5 seconds) and partial thromboplastin time at 28.1 seconds (normal: 25-35 seconds). Lactate dehydrogenase (LDH) and uric acid levels were also elevated, while triglycerides, fibrinogen, and albumin levels were normal. Autoimmune autoantibodies, viral serologies, and interferon-gamma release assay (IGRA) were all negative, excluding autoimmune hepatitis, viral hepatitis, and tuberculosis. Hematologic evaluation revealed pancytopenia with WBC 2100/μL (differential: 13% neutrophils, 56% lymphocytes, 1% monocytes, 3% immature cells), platelets 18,000/μL, RBC 3.8 million/μL, hemoglobin 10.1 g/dL, Ferritin 121 ng/mL, and reticulocyte count 0.5%, findings that also rule out hemolytic anemia. Additional investigations, including blood cultures, urinalysis, and stool examination, were unremarkable. All laboratory results are shown in Table 1.

Table 1.

Overview of Patient’s Initial Laboratory Tests.

Parameters	Result	Standard range	Parameters	Result	Standard range
RBC	3.8 million/µL	4.0-5.2 million/µL	Triglycerides	116 mg/dL	33-129 mg/dL
Hemoglobin	10.1 g/dL	10.5-14.0 g/dL	Total bilirubin	13.1 mg/dL	0.2-1.2 mg/dL
Ferritin	121 ng/mL	20-200 ng/mL	Direct bilirubin	6.43 mg/dL	0.0-0.3 mg/dL
Reticulocyte	0.5%	0.5%-1.5%	AST	1325 U/L	10-40 U/L
Platelet count	18 000/µL	150 000-450 000/µL	ALT	1283 U/L	7-35 U/L
WBC	2100/µL	4500-11 000/µL	ALP	1150 U/L	45-320 U/L
Neutrophil	13%	40%-70%	GGT	44 U/L	5-40 U/L
Lymphocyte	56%	20%-50%	PT	14.5 s	11-13.5 s
Monocyte	1%	2%-10%	PTT	28.1 s	25-35 s
Blast cells	3%	0%	HAV IgM	Negative	-
Albumin	4.36 g/dL	3.4-5.4 g/dL	HBV IgM	Negative	-
Creatinine	0.43 mg/dL	0.3-0.7 mg/dL	HBs Ag	Negative	-
Uric acid	6.9 mg/dL	2.5-6.0 mg/dL	EBV IgM	Negative	-
Fibrinogen	248 mg/dL	200-400 mg/dL	CMV IgM	Negative	-
Antinuclear Ab	Negative	-	HIV Ab	Negative	-
LDH	1674 U/L	120-300 U/L	Parvovirus B19	Negative	-
Anti-Smith antibody Ab	Negative	-	IGRA	Negative	-
Anti-liver-kidney microsomal Ab	Negative	-

Abbreviations: Ab, antibody; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HAV, hepatitis A virus; HBs Ag, hepatitis B surface antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus; IgM, immunoglobulin M; IGRA, interferon-gamma release assay; PT, prothrombin time; PTT, partial thromboplastin time.

Standard ranges represent age-specific pediatric values per hospital standards.

Bone marrow aspiration (BMA), performed due to pancytopenia, showed 80% blasts, positive for CD19, CD10, CD45, CD38, TdT, HLA-DR, CD123, and CD66c on flow cytometry, confirming precursor B-ALL. No common ALL translocations were found, and cytogenetics were normal (Figure 1). HLH was considered initially but ruled out due to absent hemophagocytosis on BMA, normal ferritin, fibrinogen triglyceride levels (Table 1), and lack of fever or splenomegaly. After excluding other etiologies, leukemic infiltration was identified as the cause of hepatic dysfunction. However, a liver biopsy to confirm leukemic infiltration was avoided due to bleeding and infection risks associated with pancytopenia. Magnetic resonance cholangiopancreatography (MRCP) also ruled out biliary obstruction and supported the findings, suggesting hepatitis secondary to leukemic infiltration.

Figure 1.

The bone marrow smear of the patient reveals cells that are 3 to 4 times larger than mature red blood cells, characterized by a high nuclear-to-cytoplasmic ratio. The cytoplasm is scant, light blue, and lacks granules, indicative of lymphoblasts (Leishman stain, ×100).

Treatment was initiated with daily divided doses of dexamethasone (6 mg/m²), with regular monitoring of vital signs and laboratory tests. Within 24 hours, Liver Function Tests (LFTs) showed significant improvement. Following 3 days of corticosteroid therapy, LFTs decreased to: ALT 529 U/L, AST 362 U/L, total bilirubin 4.61 mg/dL, and direct bilirubin 2.58 mg/dL. With rapid improvement in LFTs following steroid administration and exclusion of other hepatitis etiologies, leukemic infiltration was confirmed as the cause of ALF. Following consultation with a pediatric gastroenterologist, chemotherapy was initiated after 3 days of dexamethasone administration to reduce leukemic burden and cytokine release, thereby minimizing the risk of tumor lysis syndrome. The Children’s Oncology Group (COG) protocol AALL0932 for standard-risk B-ALL induction therapy was administered. High disease burden and persistent blastemia necessitated urgent and unadjusted treatment including intrathecal methotrexate and cytarabine, intravenous vincristine, and PEG-asparaginase with daily LFTs monitoring. The LFTs timeline and treatment regimen details are presented in Table 2.

Table 2.

Timeline of LFT Trends and Chemotherapy Regimen During the Induction Phase.

Day	Treatment	Total bilirubin (mg/dL)	Direct bilirubin (mg/dL)	AST (U/L)	ALT (U/L)	ALP (U/L)
1	Dexamethasone (6 mg/m²)	13.03	6.37	1304	1209	1201
2	Dexamethasone (6 mg/m²)	9.5	5.1	866	713	949
3	Dexamethasone (6 mg/m²)	6.7	3.9	542	631	815
4	Dexamethasone (6 mg/m²), vincristine (1.5 mg/m²)	4.61	2.58	362	529	722
5	Dexamethasone (6 mg/m²), IT cytarabine (70 mg)	3.83	2.10	293	309	681
6	Dexamethasone (6 mg/m²)	2.40	1.18	159	234	568
7	Dexamethasone (6 mg/m²)	2.50	0.95	98	187	522
8	Dexamethasone (6 mg/m²), PEG-asparaginase (2500 units/m²)	2.27	0.76	65	164	502
10	Dexamethasone (6 mg/m²)	2.01	0.51	30^*	137	452
11	Dexamethasone (6 mg/m²), vincristine (1.5 mg/m²)	1.8	0.42	36	140	410
12	Dexamethasone (6 mg/m²), IT methotrexate (15 mg)	1.1^*	0.34	40	114	383
14	Dexamethasone (6 mg/m²)	1.01	0.27^*	52	107	298^*
18	Dexamethasone (6 mg/m²), vincristine (1.5 mg/m²)	0.93	0.28	56	85	228
25	Dexamethasone (6 mg/m²), vincristine (1.5 mg/m²)	0.78	0.21	47	29^*	189
33	Dexamethasone (6 mg/m²), IT Methotrexate (15 mg)	0.71	0.20	38	33	197

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; COG: children’s oncology group; LFTs: liver function tests; PEG-asparaginase, polyethylene glycol-asparaginase.

The table presents the COG induction regimen, chemotherapy, and LFTs timeline for the patient. After 3 days of dexamethasone, a 29-day induction phase of chemotherapy started on Day 4. The regimen includes dexamethasone (6 mg/m² daily), vincristine (1.5 mg/m² on Days 4, 11, 18, 25), PEG-asparaginase (2500 units/m² on Day 8), intrathecal cytarabine (Day 5), and intrathecal methotrexate (Days 12, 33).

The first day each parameter returned to normal levels.

Follow-up showed a gradual decline in LFTs. By day 10, AST was 30 U/L, ALP was 298 on day 14, and by day 25, ALT was 29 U/L. Jaundice resolved by day 12, with total bilirubin at 1.1 mg/dL and direct bilirubin at 0.27 mg/dL by day 14, all within normal ranges. On day 29 of chemotherapy, at the end of the induction phase, repeat BMA revealed minimal residual disease (MRD) of 0.001%, correlated with decreasing LFTs, supporting continuation of chemotherapy. Subsequent improvement following chemotherapy may also suggest a multifactorial etiology, with drug-induced liver injury potentially contributing; however, leukemic infiltration remains the primary cause, as evidenced by the rapid improvement in LFTs with steroid therapy.

The patient is currently in the maintenance phase under regular hematology follow-up. After 1 year of treatment, chemotherapy has been successful, with no organomegaly, significant LFTs elevation, or jaundice observed.

Discussion

ALL is a hematologic malignancy representing approximately 25% of all pediatric cancers, characterized by uncontrolled lymphocyte proliferation.^1,2 ALL typically manifests with cytopenia (anemia, neutropenia, and thrombocytopenia) due to malignant cell replacement in BM, often includes systemic symptoms such as fever, fatigue, weight loss, and night sweats.⁸ The proliferation of immature lymphoid cells can infiltrate extramedullary sites, potentially affecting the central nervous system, testicles, liver, spleen, thymus, and lymph nodes, which can cause symptoms related to the affected organs.^4,5,9

Hepatomegaly is the most common symptom in children with ALL, with over 50% presenting with a palpable liver. However, initial ALF is rarely reported.^3,6,10,11 The mechanism of liver dysfunction is not clear but can be attributed to paraneoplastic syndrome, concomitant viral infections, sepsis, chemotherapeutic drug-induced liver injury, and lymphocyte infiltration, which is more susceptible in cases with normalized LFTs with early steroid intake.^3,11 Leukemic liver infiltration is more common in T-cell ALL, older patients, those with a high number of WBCs, and bulky disease. It is rare for B-ALL to present with ALF at the initial diagnosis.^5,12

Although Initial liver damage in acute leukemia is not typically evident in laboratory tests, postmortem studies have observed liver infiltration in more than 95% of patients with ALL.¹³ Despite the necessity of liver biopsy for early diagnosis, it is not recommended due to the increased risk of bleeding and infections.^5,11 In pediatric ALL, mild liver dysfunction is common, with about 30% of patients showing abnormal aminotransferase levels. Direct hyperbilirubinemia is seen in 3.4% of cases, but severe elevations are rarely reported.^5,14 In addition, elevated levels of LDH and uric acid are often observed in ALL-associated hepatitis.⁵

Contemporary ALL Treatment phases consist of 4 phases: induction, consolidation, intensification, and maintenance guided by risk stratification according to clinical factors. The induction phase, which generally lasts 4 to 6 weeks, has a success rate of nearly 98%.^1,15 Chemotherapeutic agents used during the induction phase could exhibit hepatotoxicity. Specifically, asparaginase and vincristine can induce liver injury due to their hepatic detoxification systems.¹⁶ In contrast, liver injury from intrathecal methotrexate and cytarabine is uncommon.^17,18

In cases with elevated conjugated bilirubin or transaminase levels, dose reduction or delayed chemotherapy, combined with initial steroid administration, is recommended.^5,19 However, some studies have reported that, in cases similar to ours, initiating full-dose chemotherapy after corticosteroid therapy can lead to a rapid and significant decline in transaminase and bilirubin levels, without major complications and with leukemia cure rates comparable to those in patients without hepatitis.^3,5,11 Glucocorticoids are a key part of induction, inducing leukemic cell apoptosis and providing prognostic insights based on treatment response.²⁰ as observed in our case during chemotherapy. Preventive measures, including ursodiol administration and LFTs monitoring, should also be considered, with plans to consider withholding chemotherapy if an elevation in LFTs occurs.^13,21

Pediatric ALL presenting with ALF has not been widely reported. Four cases with similar presentations are summarized in Table 3. All patients presented with jaundice, markedly elevated transaminases, and hyperbilirubinemia. A liver biopsy was only performed in the report by Ford et al when the etiology remained unidentified during the initial evaluation. Despite variations in clinical presentation, each case received corticosteroids prior to chemotherapy. However, no consensus exists regarding dose reduction or the optimal timing for initiating chemotherapy following steroid therapy. Notably, all cases achieved successful treatment outcomes accompanied by improvement in LFTs.^3,11,21,22

Table 3.

Previous Cases of Childhood ALL Presenting as ALF.

Authors/journal/year	Age/gender	Presenting features	Management	Outcomes
Bhatnagar et al/Indian Pediatric Case Reports/2023³	12-y-old boy	Abdominal pain and distention, jaundice, hepatosplenomegaly, and fever. Total bilirubin = 5.5 mg/dL, direct bilirubin = 3.12 mg/dL, AST = 178, ALT = 52, and ALP = 639 U/L. Liver biopsy: not mentioned.	Prednisolone initiated, followed by ICiCLe Intermediate Risk Protocol chemotherapy with dose adjustments for hepatic failure. Full-dose chemotherapy resumed after LFTs improved.	Transaminitis resolved, bilirubin normalized by day 28, liver and spleen size reduced, no blasts by day 8, ongoing IciCLe chemotherapy.
Gu et al/Molecular and Clinical Oncology/2019¹¹	15-y-old boy	Jaundice, vomiting, tiredness, and splenomegaly. Total bilirubin = 11.7 mg/dL, direct bilirubin = 7.4 mg/dL, AST = 477 IU/L, ALT = 492 IU/L, LDH = 1255. Liver biopsy: not performed.	Liver-protective transfusions and low-dose dexamethasone for 5 d. Full-dose induction therapy after LFTs improvement.	Symptoms improved, and LFTs decreased.
Ford et al/Sage Open Medical Case Reports/2019²¹	7-y-old boy	Cholestasis, hepatosplenomegaly, jaundice, vomiting. Total bilirubin = 9.3 mg/dL, direct bilirubin = 6.8 mg/dL, AST = 1693 U/L, ALT = 1295 U/L. Liver biopsy: performed.	3 wk of corticosteroids, followed by induction chemotherapy with adjusted vincristine and daunorubicin, alongside dexamethasone.	Decreased LFTs. Completed induction. No significant complications noted.
Chang et al/Journal of Pediatric Hematology/Oncology/2011²²	15-y-old boy	Fever, abdominal pain, jaundice, vomiting, hepatosplenomegaly. Total bilirubin = 31.7 mg/dL, direct bilirubin = 25.5 mg/dL, AST = 2195 U/L, ALT = 2877 U/L, ferritin = 12,426.8 mg/L. Liver biopsy: not performed.	Antibiotics, IVIG, prednisolone, and etoposide, followed by TPOG 2002 HR protocol chemotherapy.	LFTs normalized after 1 mo. Complete remission with normal liver function.

Abbreviations: ALL, acute lymphoblastic leukemia; ALF, acute liver failure; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICiCLe, Indian Collaborative Childhood Leukemia Group; IVIG, intravenous immunoglobulin; LFTs, liver function tests; TPOG, Taiwan Pediatric Oncology Group.

Although chemotherapy-induced toxicity may cause morbidity and mortality, changes in total bilirubin, AST, and ALT levels during diagnosis and post-induction in patients with acute leukemia can lead to treatment delays, potentially increasing the risk of hepatotoxicity-related death.¹⁶ However, early treatment has been associated with improved long-term survival rates.^11,23 Given the high leukemic burden and persistent blastemia, the medical team opted for early initiation of therapy to prevent further hepatic injury.

Conclusion

A rare pediatric B-ALL case presenting initial symptomatic hepatitis with transaminases over 1000 U/L and significant hyperbilirubinemia highlights the diagnostic challenge of initial hepatitis in ALL, where leukemic infiltration, drug toxicity, and infections must be considered. The significant LFTs improvement following steroids and MRD results supported leukemic infiltration as the etiology, justifying chemotherapy continuation. This allowed full-dose induction therapy without hepatic complications despite initial risks and underscores the need for multidisciplinary monitoring. Future studies should optimize specific regimens and explore biomarkers to predict hepatotoxicity risk in similar patients.

Footnotes

Acknowledgements

We thank the Department of Clinical Research Development Unit of Amirkabir Hospital in Arak for their support in the preparation of this report.

ORCID iD

Mahbod Soltani

Ethical Considerations

This case report was approved by the Research Ethics Committee of Arak University of Medical Sciences (Approval ID: IR.ARAKMU.REC.1403.318, Date: 2024-12-29).

Consent to Participate

Written informed consent was obtained from the parents, with consideration of the child’s rights and autonomy. The parents had a prospective understanding of the treatment plan based on their child’s condition prior to study initiation, and the patient provided age-appropriate verbal assent.

Consent for Publication

Written informed consent was obtained from the patient and his parents. No identifiable information or images were included.

Author Contributions

AL: Conceptualization, Supervision, Validation. MS: Investigation; Writing—original draft; Writing—review and editing, Project Administration. MSZ: Data Curation, Methodology. NP: Validation, Investigation, Writing—Review and Editing. AHR: Resources, Writing—Review and Editing.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

Data will be made available to other authors upon reasonable request.

Presentation(s) or Awards at a Meeting

None.

Use of Artificial Intelligence (AI)-Assisted Technologies

During the preparation of this work, the authors used ChatGPT-4.0 for language editing and improving the readability based on Sage policy on AI usage.

References

Inaba

Pui

CH.

Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10(9):1926.

Huang

Liao

Yen

SJ.

Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: molecular pathways and disease treatments. Oncol Lett. 2020;20(1):448-454.

Bhatnagar

Kumar

Hemal

Acute liver failure as a presenting feature in an adolescent with acute lymphoblastic leukemia. Indian Pediatrics Case Reports. 2023;3(3):146-149.

Heincelman

Karakala

Rockey

DC.

Acute lymphoblastic leukemia in a young adult presenting as hepatitis and acute kidney injury. J Investig Med High Impact Case Rep. 2016;4(3):232470961666586. doi:10.1177/2324709616665866

Segal

Rassekh

Bond

Senger

Schreiber

RA.

Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;55(3):434-439.

Felice

Hammermuller

De Dávila

, et al. Acute lymphoblastic leukemia presenting as acute hepatic failure in childhood. Leuk Lymphoma. 2000;38(5-6):633-637.

Mekonnen

Wondmeneh

TG.

Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction. Sci Rep. 2022;12(1):13215.

Puckett

Chan

Acute lymphocytic leukemia. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025 [updated 2023 Aug 26; cited 2025 Jun 01]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459149/

Jabbour

Faderl

Kantarjian

HM.

Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005;80(11):1517-1527.

10.

Clarke

Van den Bruel

Bankhead

Mitchell

Phillips

Thompson

MJ.

Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. Arch Dis Child. 2016;101(10):894-901.

11.

Xiang

Suo

Yuan

Acute lymphoblastic leukemia in an adolescent presenting with acute hepatic failure: a case report. Mol Clin Oncol. 2019;11(2):135-138.

12.

Rastogi

Baveja

Acute lymphoblastic leukemia presenting as hepatitis in a young adult: an autopsy presentation. D Y Patil Journal of Health Sciences. 2023;11(2):110-113.

13.

Mudd

Guddati

AK.

Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(7):3461-3474.

14.

Kelleher

Monteleone

Steele

Gang

Angelides

AG.

Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001;23(2):117-121.

15.

Inaba

Mullighan

CG.

Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524-2539.

16.

Islam

Rahman

AKMS

Hasan

, et al. Liver function tests in patients of acute leukemia before and after induction chemotherapy. J Biosci Med. 2020;08(02):110-121.

17.

Flannery

Thompson Bastin

ML.

Acute hepatotoxicity after high-dose cytarabine for the treatment of relapsed acute myeloid leukemia: a case report. Hosp Pharm. 2019;54(3):160-164.

18.

Gopalakrishna

Hercun

Shah

Roschewski

Rotman

Acute transient aminotransferase elevation is common with intrathecal methotrexate, but liver injury is infrequent. Liver Int. 2025;45(3):e70022.

19.

Venvertloh

Karp

Ghantarchyan

Raoufi

A rare case: acute liver injury uncovering a diagnosis of B-cell acute lymphoblastic leukemia in a young adult. Cureus. 2023;15(2):e35274.

20.

Gao

Liu

WJ.

Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22(22):7858-7866.

21.

Ford

Rainey

Hanson

Kendhari

Acute lymphoblastic leukemia presenting as cholestatic jaundice in a 7-year-old boy. Sage Open Med Case Rep. 2019;7:2050313X1987531.

22.

Chang

Chen

, et al. Acute lymphoblastic leukemia presented as severe jaundice and hyperferritinemia: a case report. J Pediatr Hematol Oncol. 2011;33(3):e117-e119.

23.

Ribera

Genescà

Treatment of adolescent and young adults with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014052.